How do I install the Endo Sdm Antipsychotic skill?

Run npx skillmds@latest add dromlakhani/endo-sdm-antipsychotic in your terminal (requires Node.js), paste this page's agent-chat prompt into Claude, Cursor, or any MCP-connected agent, or download the SKILL.md file and copy it into your agent's skills directory.

Is Endo Sdm Antipsychotic safe to use?

SkillMD's automated safety review verdict for this skill is PASS. Independent scanners report: SkillSpector: PASS, Skill Scanner: PASS. Capability flags: docs only. SkillMD never runs a skill's scripts for you; review the SKILL.md before installing.

Which AI agents work with Endo Sdm Antipsychotic?

This skill is tagged as working with Claude Code, Claude.ai, OpenAI Codex. SKILL.md is an open format, so most agents that read a skills directory can load it too.

Is Endo Sdm Antipsychotic free to use?

Yes. Installing skills from SkillMD is free, and the skill stays under its author's original license.

Who published Endo Sdm Antipsychotic?

dromlakhani (@dromlakhani) published this skill. Their other Agent Skills are listed on their SkillMD profile.

Endo Sdm Antipsychotic by dromlakhani

Name: Endo Sdm Antipsychotic
Rating: 4.2 (5 reviews)
Author: dromlakhani

Endo Sdm Antipsychotic

Recommends using weight‑neutral antipsychotic alternatives when possible and employing shared decision‑making that provides quantitative estimates of expected weight effect to guide drug choice. Triggered when a clinician asks, “How do I involve this patient in choosing an antipsychotic with minimal weight gain?” or “What resources show weight‑change projections for risperidone vs aripiprazole?”.

dromlakhani Updated Aug 19, 2026 10 repo stars

File contents

Shared decision‑making for antipsychotics with weight‑effect estimates

STEP 1 — Gather Information

Collect psychiatric indication, current weight and BMI, prior weight changes with psychotropics, patient’s weight‑related concerns and preferences, baseline metabolic labs (glucose, lipids), and any contraindications to specific agents.

STEP 2 — Rule In / Rule Out

Is an antipsychotic clinically indicated for the patient’s condition?

No: Consider non‑pharmacologic therapies or alternative medication classes; revisit if symptoms persist.
Yes: Proceed to classify available antipsychotic options by weight effect.

STEP 3 — Classify or Stratify

Stratify candidate antipsychotics into weight‑neutral (e.g., aripiprazole, ziprasidone, lurasidone) and weight‑gain (e.g., olanzapine, clozapine, quetiapine, risperidone) groups using published mean weight‑change data over 12 weeks:

Aripiprazole ≈ +0.5 kg, Ziprasidone ≈ 0 kg, Lurasidone ≈ +0.2 kg
Risperidone ≈ +2 kg, Quetiapine ≈ +2.5 kg, Olanzapine ≈ +4.5 kg, Clozapine ≈ +3.5 kg
Create a shortlist that matches efficacy needs with the lowest expected weight impact.

STEP 4 — Decide

Engage in shared decision‑making using a decision aid that presents the quantitative weight‑change estimates alongside efficacy, side‑effect profile, and cost; select the agent that best balances therapeutic goals and weight concerns; document the discussion, the patient’s values, and the agreed‑upon prescription.

Clinical Guardrails / Mimics / Pitfalls

Do not default to high‑risk weight‑gain agents (olanzapine, clozapine) in patients with obesity or metabolic syndrome without explicit discussion of weight impact; avoid ignoring the patient’s weight‑related values; do not rely solely on efficacy data when choosing antipsychotics; monitor weight at baseline and regularly (e.g., monthly for the first 3 months, then quarterly) to detect early changes.

Concrete Clinical Example

A 32‑year‑old man with schizophrenia, BMI 29 kg/m², reports worsening psychosis and worries about weight gain. The clinician discusses options: aripiprazole (expected weight change +0.5 kg over 12 weeks) versus olanzapine (+4.5 kg). The patient chooses aripiprazole; treatment starts at 5 mg daily with a weight check scheduled in 4 weeks.

Source: Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415

---name: endo-sdm-antipsychoticdescription: Recommends using weight‑neutral antipsychotic alternatives when possible and employing shared decision‑making that provides quantitative estimates of expected weight effect to guide drug choice. Triggered when a clinician asks, “How do I involve this patient in choosing an antipsychotic with minimal weight gain?” or “What resources show weight‑change projections for risperidone vs aripiprazole?”.---# Shared decision‑making for antipsychotics with weight‑effect estimates## STEP 1 — Gather InformationCollect psychiatric indication, current weight and BMI, prior weight changes with psychotropics, patient’s weight‑related concerns and preferences, baseline metabolic labs (glucose, lipids), and any contraindications to specific agents.## STEP 2 — Rule In / Rule OutIs an antipsychotic clinically indicated for the patient’s condition? - **No:** Consider non‑pharmacologic therapies or alternative medication classes; revisit if symptoms persist. - **Yes:** Proceed to classify available antipsychotic options by weight effect.## STEP 3 — Classify or StratifyStratify candidate antipsychotics into weight‑neutral (e.g., aripiprazole, ziprasidone, lurasidone) and weight‑gain (e.g., olanzapine, clozapine, quetiapine, risperidone) groups using published mean weight‑change data over 12 weeks: - Aripiprazole ≈ +0.5 kg, Ziprasidone ≈ 0 kg, Lurasidone ≈ +0.2 kg - Risperidone ≈ +2 kg, Quetiapine ≈ +2.5 kg, Olanzapine ≈ +4.5 kg, Clozapine ≈ +3.5 kg Create a shortlist that matches efficacy needs with the lowest expected weight impact.## STEP 4 — DecideEngage in shared decision‑making using a decision aid that presents the quantitative weight‑change estimates alongside efficacy, side‑effect profile, and cost; select the agent that best balances therapeutic goals and weight concerns; document the discussion, the patient’s values, and the agreed‑upon prescription.## Clinical Guardrails / Mimics / PitfallsDo not default to high‑risk weight‑gain agents (olanzapine, clozapine) in patients with obesity or metabolic syndrome without explicit discussion of weight impact; avoid ignoring the patient’s weight‑related values; do not rely solely on efficacy data when choosing antipsychotics; monitor weight at baseline and regularly (e.g., monthly for the first 3 months, then quarterly) to detect early changes.## Concrete Clinical ExampleA 32‑year‑old man with schizophrenia, BMI 29 kg/m², reports worsening psychosis and worries about weight gain. The clinician discusses options: aripiprazole (expected weight change +0.5 kg over 12 weeks) versus olanzapine (+4.5 kg). The patient chooses aripiprazole; treatment starts at 5 mg daily with a weight check scheduled in 4 weeks.**Source:** Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2015, DOI:10.1210/jc.2014-3415

Frequently asked questions